Axe Compute INC. (AGPU) — SEC Filings

Overview

Axe Compute INC. (AGPU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 23, 2026: On March 6, 2026, Charles Lee Sr. Nuzum reported a change in beneficial ownership of securities for Axe Compute Inc. The filing details transactions related to his holdings, but specific dollar amounts and the exact nature of the transactions are not provided in this summary.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 7 bearish, 42 neutral, 1 mixed. The dominant filing sentiment for Axe Compute INC. is neutral.

Filing Type Overview

Axe Compute INC. (AGPU) has filed 1 4, 38 8-K, 6 10-Q, 3 DEF 14A, 1 8-K/A, 1 10-K with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Axe Compute Inc. Insider Ownership Change — 4 · Apr 23, 2026 Risk: low
  On March 6, 2026, Charles Lee Sr. Nuzum reported a change in beneficial ownership of securities for Axe Compute Inc. The filing details transactions related to
• 8-K Filing — 8-K · Apr 22, 2026
• Axe Compute Inc. Files 8-K: Officer Changes & More — 8-K · Apr 1, 2026 Risk: medium
  Axe Compute Inc. filed an 8-K on April 1, 2026, reporting changes in officers and compensatory arrangements. The filing also includes other events and financial
• Axe Compute Inc. Reports Board and Executive Changes — 8-K · Dec 12, 2025 Risk: medium
  Axe Compute Inc. announced on December 10, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of
• Predictive Oncology Files 8-K with Corporate Updates — 8-K · Dec 11, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on December 11, 2025, reporting events as of December 9, 2025. The filing indicates amendments to its Articles of Incorpor
• Predictive Oncology Files 8-K with Financials — 8-K · Dec 2, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on December 2, 2025, reporting on events as of December 1, 2025. The filing includes financial statements and exhibits, wi
• 8-K Filing — 8-K · Nov 25, 2025
• Predictive Oncology Inc. Files 8-K — 8-K · Nov 20, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on November 20, 2025, reporting "Other Events." The filing indicates the company was formerly known as Skyline Medical Inc
• 8-K Filing — 8-K · Nov 17, 2025
• POAI's Q3 Net Loss Soars to $77.6M Amid Crypto Strategy Shift — 10-Q · Nov 14, 2025 Risk: high
  Predictive Oncology Inc. (POAI) reported a significant net loss of $77,651,843 for the three months ended September 30, 2025, a substantial increase from a net
• Predictive Oncology Files 8-K — 8-K · Oct 29, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on October 29, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Skyl
• Predictive Oncology Seeks Shareholder Nod on Dilution, Board Seats — DEF 14A · Oct 27, 2025 Risk: high
  Predictive Oncology Inc. (AGPU) is holding its Annual Meeting on November 25, 2025, to address several critical proposals. Shareholders will vote on the electio
• Predictive Oncology Files 8-K on Shareholder Nominations — 8-K · Oct 16, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K on October 16, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the
• Predictive Oncology Files 8-K — 8-K · Oct 8, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on October 8, 2025, reporting on events that occurred on October 7, 2025. The filing indicates a Regulation FD Disclosure
• Predictive Oncology Inc. Files 8-K with Material Agreements & Officer Changes — 8-K · Sep 30, 2025 Risk: medium
  Predictive Oncology Inc. announced on September 25, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equit
• Predictive Oncology Files 8-K — 8-K · Sep 29, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on September 29, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerl
• Predictive Oncology Files 8-K on Security Holder Matters — 8-K · Sep 25, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K on September 25, 2025, reporting events that occurred on September 19, 2025. The filing indicates material modifications t
• Predictive Oncology Files 8-K: Director & Officer Changes — 8-K · Sep 12, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K on September 12, 2025, reporting events on September 9, 2025. The filing indicates changes related to the departure and el
• Predictive Oncology Files 8-K on Material Agreement & Equity Sales — 8-K · Sep 2, 2025 Risk: medium
  Predictive Oncology Inc. entered into a material definitive agreement on August 26, 2025. The company also reported on unregistered sales of equity securities.
• Predictive Oncology Files Definitive Proxy Statement — DEF 14A · Aug 18, 2025 Risk: low
  Predictive Oncology Inc. filed a Definitive Proxy Statement (DEF 14A) on August 18, 2025, for the fiscal year ending December 31, 2025. The filing pertains to t
• Predictive Oncology Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on August 14, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Ex
• Predictive Oncology Narrows Loss Amid Revenue Plunge, Delisting Threat — 10-Q · Aug 13, 2025 Risk: high
  Predictive Oncology Inc. (POAI) reported a net loss of $2.07 million for the three months ended June 30, 2025, a significant improvement from the $3.18 million
• Predictive Oncology Acquires Bio-Genetics, Raises $1.5M — 8-K · Jul 24, 2025 Risk: medium
  Predictive Oncology Inc. announced on July 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of privately held Bio-Gen
• Predictive Oncology Inc. Files 8-K — 8-K · Jul 18, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on July 18, 2025, reporting on events and financial statements as of December 31, 2024. The company, formerly known as Sky
• Predictive Oncology Faces Delisting Concerns — 8-K · Jul 11, 2025 Risk: high
  Predictive Oncology Inc. filed an 8-K on July 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The specific
• Predictive Oncology Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 8, 2025 Risk: medium
  Predictive Oncology Inc. entered into a material definitive agreement on July 1, 2025. The company also reported on unregistered sales of equity securities and
• Predictive Oncology Faces Delisting Concerns — 8-K · Jun 11, 2025 Risk: high
  Predictive Oncology Inc. filed an 8-K on June 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing a
• Predictive Oncology Files 8-K — 8-K · Jun 6, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on June 6, 2025, reporting an event that occurred on June 2, 2025. The filing is categorized under 'Other Events' and incl
• Predictive Oncology Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Predictive Oncology Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Predictive Oncology Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Skyline Medical Inc., is based in Pittsburgh, PA. T
• Predictive Oncology Files 8-K/A Amendment — 8-K/A · Apr 18, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K/A amendment on April 18, 2025, to report an event that occurred on April 3, 2025. The filing pertains to 'Other Events' an
• Predictive Oncology Files 8-K — 8-K · Apr 7, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on April 7, 2025, reporting an event that occurred on April 3, 2025. The filing is categorized under Regulation FD Disclos
• Predictive Oncology Files 8-K on Financials — 8-K · Apr 1, 2025 Risk: low
  Predictive Oncology Inc. filed an 8-K on April 1, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Predictive Oncology Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Predictive Oncology Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Skyline Me
• Predictive Oncology Inc. Files 8-K for Material Agreement — 8-K · Mar 20, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K on March 20, 2025, reporting a material definitive agreement entered into on March 14, 2025. The filing also includes othe
• Predictive Oncology Inc. Files 8-K for Material Agreement — 8-K · Mar 5, 2025 Risk: medium
  Predictive Oncology Inc. entered into a Material Definitive Agreement on February 28, 2025. The filing also includes financial statements and exhibits related t
• Predictive Oncology Inc. Files 8-K for Material Agreement — 8-K · Feb 19, 2025 Risk: medium
  Predictive Oncology Inc. announced on February 18, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales o
• Predictive Oncology Files 8-K with Material Agreement — 8-K · Jan 6, 2025 Risk: medium
  Predictive Oncology Inc. filed an 8-K on January 6, 2025, reporting a material definitive agreement. The filing also includes financial statements and exhibits.
• Predictive Oncology Files Definitive Proxy Statement — DEF 14A · Nov 27, 2024 Risk: low
  Predictive Oncology Inc. filed a Definitive Proxy Statement (DEF 14A) on November 27, 2024, for the fiscal year ending December 30, 2024. The company, formerly
• Predictive Oncology Faces Delisting Concerns — 8-K · Nov 22, 2024 Risk: high
  Predictive Oncology Inc. filed an 8-K on November 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerl
• Predictive Oncology Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  Predictive Oncology Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Predictive Oncology Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Predictive Oncology Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Skyline Medical Inc., reported financial result
• Predictive Oncology Faces Nasdaq Delisting Warning — 8-K · Sep 20, 2024 Risk: high
  Predictive Oncology Inc. received a notice on September 19, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Marke
• Predictive Oncology Files 8-K on Financials — 8-K · Aug 14, 2024 Risk: low
  Predictive Oncology Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Predictive Oncology Files Q2 2024 10-Q, Reports Warrant Events — 10-Q · Aug 13, 2024 Risk: medium
  Predictive Oncology Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities. Key even
• Predictive Oncology Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 29, 2024 Risk: medium
  Predictive Oncology Inc. announced on July 25, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of eq
• Predictive Oncology Files 8-K — 8-K · May 30, 2024 Risk: low
  Predictive Oncology Inc. filed an 8-K on May 30, 2024, reporting an event that occurred on May 28, 2024. The filing is categorized under 'Other Events' and 'Fin
• Predictive Oncology Inc. Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  Predictive Oncology Inc. filed an 8-K on May 15, 2024, reporting on its financial condition and results of operations. The filing details the company's business
• Predictive Oncology Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024 Risk: low
  Predictive Oncology Inc. (AGPU) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Predictive Oncology Inc. filed its 10-Q report for the period endi
• Predictive Oncology Enters Material Definitive Agreement — 8-K · May 6, 2024 Risk: medium
  Predictive Oncology Inc. announced on May 3, 2024, that it entered into a material definitive agreement. The company, formerly known as Skyline Medical Inc., is

Risk Profile

Risk Assessment: Of AGPU's 47 recent filings, 7 were flagged as high-risk, 20 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Axe Compute INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $3,618
• Net Income: -$77,651,843
• EPS: -$107.25
• Cash Position: $181,667
• Total Assets: $3,137,298
• Total Debt: $80,565,220

Key Executives

• Charles Lee Sr. Nuzum
• 0001346421
• Cryptocurrency Subcommittee
• Chief Investment Officer
• Daniel E. Handley, M.S., Ph.D.
• Chuck Nuzum
• Raymond Vennare

Industry Context

Predictive Oncology operates in the biotechnology and healthcare technology sector, focusing on AI-driven solutions for cancer treatment. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and substantial funding to advance their platforms.

Top Tags

material-agreement (9) · company-update (8) · 8-K (7) · financial-reporting (7) · filing (6) · corporate-actions (5) · corporate-governance (5) · financials (5) · equity-sale (5) · delisting (4)

Key Numbers

• Filing Date: 2026-04-23 — Date the ownership change was reported
• Period of Report: 2026-03-06 — Date of the reported ownership change
• Documents: 15 — Number of documents included in the filing
• Net Loss (Q3 2025): $77.65M — Increased significantly from $3.09M in Q3 2024, primarily due to derivative loss.
• Loss on Derivative Instruments (Q3 2025): $74.37M — Directly attributable to the Aethir token Treasury Strategy.
• Cash and Cash Equivalents (Sept 30, 2025): $181,667 — Decreased from $611,822 at Dec 31, 2024, before subsequent private placements.
• Proceeds from Private Placements (Oct 7, 2025): $50.8M — Expected to fund operations for at least 12 months, addressing going concern doubts.
• Reverse Stock Split: 1-for-15 — Effective September 29, 2025, to maintain Nasdaq compliance.
• Revenue (9 Months Ended Sept 30, 2025): $116,610 — Increased from $76,020 in the prior year period.
• Net Loss (9 Months Ended Sept 30, 2025): $82,165,178 — Significantly higher than $10,494,794 in the prior year period.
• Net Loss per Common Share (Q3 2025): $107.25 — Increased from $7.26 in Q3 2024, reflecting the large net loss and reverse stock split.
• Shares from pre-funded warrants: 14,903,393 shares — Potential issuance, representing significant dilution
• Shares outstanding: 3,501,430 shares — Total shares entitled to vote as of October 24, 2025
• Annual Meeting Date: November 25, 2025 — Date shareholders will vote on key proposals
• Record Date: October 24, 2025 — Date for determining eligible voters

Related Companies

POAI · RENB · PRED

Frequently Asked Questions